NanoString Launches the CosMx 6,000 plex RNA Assay and Showcases Whole Transcriptome Imaging Capability
- None.
- None.
Insights
The introduction of NanoString Technologies' CosMx Human 6K Discovery Panel represents a significant advancement in spatial biology technology. This new tool allows researchers to measure over 6,000 RNA targets, enhancing the granularity with which biological pathways can be studied. From a market perspective, this innovation could position NanoString as a leader in the rapidly growing field of spatial genomics, which is expected to influence drug discovery, diagnostics and personalized medicine.
As NanoString gears up for the commercial launch of its Whole Transcriptome Panel in 2025, the company is likely to see increased interest from academic and pharmaceutical research entities. This could translate into higher demand for its products, potentially increasing revenue streams and influencing stock market performance positively. Investors should monitor adoption rates and any partnerships or collaborations that may arise from these initial presentations and the AGBT meeting.
The CosMx Whole Transcriptome Panel's ability to analyze almost 19,000 genes at single-cell and subcellular resolution is a game-changer for medical research. The detailed insights into the genomic signatures of diseases like Alzheimer's and colorectal cancer could accelerate the development of targeted therapies and improve diagnostic accuracy.
For stakeholders in the medical research industry, this technology may represent a pivotal shift towards more precise and effective treatment strategies. The long-term implications for patient outcomes and healthcare costs could be profound, with the potential to reduce the burden of chronic diseases significantly. The presentations by Dr. Orr and Dr. Heyn at the AGBT meeting will be critical in demonstrating the real-world applications and benefits of this technology.
The commercialization of the CosMx Human 6K Discovery Panel and the future Whole Transcriptome Panel will likely require careful navigation of regulatory landscapes, particularly concerning intellectual property and FDA approvals. Patent protection will be crucial for NanoString to secure its market position and capitalize on its research and development investments.
Furthermore, as the technology is adopted and potentially integrated into diagnostic processes, compliance with healthcare regulations, including the Health Insurance Portability and Accountability Act (HIPAA) in the U.S., will become increasingly important. Companies and investors should be aware of the legal and regulatory challenges that could impact the speed at which these products reach the market and their subsequent adoption.
Three customers will present inaugural studies powered by the novel CosMx Whole Transcriptome Panel during annual AGBT meeting
Under the banner, “Plex YES!”, a theme inspired by customer reactions to the high plex CosMx Human 6K Discovery Panel, NanoString team members and early access researchers will highlight the CosMx SMI’s expanded capabilities with the official product launch at the annual AGBT meeting. These will include showcasing superior cell segmentation, genomic breadth, and capacity to profile genes across nearly every biological pathway and over 400 ligand-receptor pairs.
With the recently announced achievement of the whole transcriptome prototype panel on the CosMx SMI, researchers can now analyze almost 19,000 genes at true single-cell and subcellular resolution. Dr. Miranda Orr of Wake Forest University School of Medicine, Dr. Holger Heyn of Centro Nacional de Análisis Genómico, and Dennis Hua Gong of Massachusetts General Hospital and Harvard University will present novel research representing the first studies powered by whole transcriptome imaging.
"The CosMx Whole Transcriptome Panel is the ultimate tool for spatial biology; it resulted in new discoveries on my first run. I know I’m getting the maximum amount of data possible from precious tissue samples. It eliminates the tradeoff between resolution and plex," said Miranda Orr, Ph.D., of Wake Forest University School of Medicine. Following early access to the product, Dr. Orr observed, "The panel is advancing the understanding of senescent cells and unraveling the genomic signatures underlying their role in Alzheimer's Disease.”
Describing the CosMx Whole Transcriptome Panel as “groundbreaking technology,” Dr. Heyn predicts, “it will change the way my lab addresses the most challenging research questions, and undoubtedly, it will advance our understanding of colorectal cancer, paving the way for significant improvements in diagnostics and targeted therapies."
NanoString’s spatial solutions will be featured in ten AGBT-accepted abstracts, including two independent academic researchers presenting data on the company’s ground-breaking innovation, whole transcriptome imaging on the CosMx SMI.
CosMx Whole Transcriptome Panel:
- “Spatio-temporal dissection of colorectal cancer initiation using Whole Transcriptome imaging,” presented by Holger Heyn, Ph.D., of Centro Nacional de Análisis Genómico, Tuesday, February 6, 8:50-9:10 PM ET.
- “Integration of Live Cell Holotomography and Single Cell Spatial Transcriptomics to Visualize Acquired and Intrinsic Resistance to Targeted Therapy,” single cell analysis, integrating in-depth analysis of cell morphologies via label-free live cell holotomography leveraging the CosMx SMI’s Whole Transcriptome analysis to examine cell phenotypes and genetic response to perturbations, a poster flash talk presented by Dennis Hua Gong, of Massachusetts General Hospital and Harvard University, Tuesday, February 6 at 11:25 AM ET.
- “Ultra-high plex single-cell spatial multi-omic imaging of tau neuropathology in human brain sections,” a 64-plex protein and whole transcriptome RNA imaging study accomplished from the same sample revealing spatial correlations of tau proteins with gene expression in Alzheimer’s disease, presented by Miranda Orr, Ph.D., of Wake Forest University School of Medicine, Wednesday, February 7, 8:50-9:10 PM ET.
CosMx Human 6K Discovery Panel & CosMx Whole Transcriptome Panel:
- “NanoString Spatial Biology Roadmap: The Holy Grail of Spatial is Here,” presented by Joseph Beechem, Ph.D., Chief Scientific Officer, NanoString, Wednesday, February 7, 3:35-3:50 PM ET.
GeoMx DSP and CosMx SMI:
- “The Spatial Atlas of Human Anatomy (SAHA) project: unveiling cellular landscapes and orchestrating a new paradigm in precision medicine,” a foundational database for benchmarking spatial medicine, an update on the first samples analyzed using GeoMx Digital Spatial Profiler and CosMx SMI, presented by Jiwoon Park, Ph.D., of Weill Cornell Medicine, Tuesday, February 6, 4:20-4:40 PM ET.
To celebrate the launch and commercial shipment of the CosMx Human 6K Discovery Panel, NanoString invites AGBT attendees to participate in “6K All Day!” and welcomes AGBT attendees to visit its booth,
NanoString plans to make the CosMx Human Whole Transcriptome panel commercially available in 2025.
About NanoString
NanoString Technologies, a leader in spatial biology, offers an ecosystem of innovative discovery and translational research solutions, empowering our customers to map the universe of biology. The GeoMx® Digital Spatial Profiler is a flexible and consistent solution combining the power of whole tissue imaging with gene expression and protein data for spatial whole transcriptomics and proteomics. The CosMx™ Spatial Molecular Imager is a single-cell imaging platform powered by spatial multiomics enabling researchers to map single cells in their native environments to extract deep biological insights and novel discoveries from one experiment. The AtoMx™ Spatial Informatics Platform is a cloud-based informatics solution with advanced analytics and global collaboration capabilities, enabling powerful spatial biology insights anytime, anywhere. At the foundation of our research tools is our nCounter® Analysis System, which offers a secure way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision.
For more information, please visit www.nanostring.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding our plans to commercially launch and ship new product offerings in the future and expectations about demand for our products. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include market acceptance of our products; adverse conditions in the general domestic and global economic markets; the effects of ongoing litigation; the impact of competition; the impact of expanded sales, marketing, and product development on operating expenses; delays or other unforeseen problems with respect to manufacturing and product development; as well as the other risks set forth in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. NanoString Technologies disclaims any obligation to update these forward-looking statements.
NanoString, NanoString Technologies, the NanoString logo, GeoMx, AtoMx and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.
This news release may include information regarding CosMx™ SMI products for RNA detection, products that are not available in the member states of the European Unified Patent Court. Such limitations are further described here.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240201133172/en/
Meg O’Conor
Director of Public Relations
MOConor@NanoString.com
Phone: 206-735-8495
Source: NanoString Technologies, Inc.
FAQ
What is the CosMx Whole Transcriptome Panel?
What is the significance of the CosMx Human 6K Discovery Panel?
What research studies will be presented at the AGBT General Meeting?
What are the future commercial availability plans for the CosMx Human Whole Transcriptome panel?
